Answers are grounded in this paper and cite their sources.
Solution phase affinity constants of the glycopeptide antibiotic alpha- and beta-avoparcin, with a range of bacterial cell-wall receptor-mimicking model peptides, were determined by a relatively new method: affinity electrospray ionization mass spectrometry (ESI-MS). This method is relatively efficient and allows the parallel determination of several affinity constants in mixtures of antibiotics and receptors. The determined binding constants for alpha- and beta-avoparcin were compared with those of the related glycopeptide antibiotic vancomycin. The solution phase binding affinities of alpha- and beta-avoparcin on one hand, and vancomycin on the other, were found to be in the same order, at least for the range of receptor-mimicking peptides studied. However, beta-avoparcin displayed slightly higher binding affinities than alpha-avoparcin, particularly for strong binding receptor-mimicking peptides. The evidence that alpha- and beta-avoparcin and vancomycin are structurally similar, combined with the present data revealing their similar affinity for bacterial cell-wall receptor-mimicking peptides, supports the hypothesis that the appearance of vancomycin-resistant enterococci (VRE) might be linked to the widespread use of avoparcin.
No takes yet. Share an insight, caveat, or question.
Hoof et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: